An adjuvant autologous therapeutic vaccine %2525252528HSPPC-…
An adjuvant autologous therapeutic vaccine %2525252528HSPPC-96%252525253B vitespen%2525252529 versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma%252525253A a multicentre%252525252C open-label%252525252C randomised phase III trial.
Article, Chapter
Full text availability for this item
Journal:
Lancet, TheOpens in new Window
Coverage:
- 1823-10-05~present; volume:1~present;issue:1~present